Development of CAR-T cell therapy for B-ALL using a point-of-care approach

Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and face bottlenecks like complex scaling up, high costs, and logistic operations. These difficulties ar...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology
Main Authors: de Macedo Abdo, Luiza, Barros, Luciana Rodrigues Carvalho, Saldanha Viegas, Mariana, Vieira Codeço Marques, Luisa, de Sousa Ferreira, Priscila, Chicaybam, Leonardo, Bonamino, Martín Hernán
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2020
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185214/
https://ncbi.nlm.nih.gov/pubmed/32363126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1752592
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items